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Abstract 
Background: The mechanisms of steroids actions in the brain mainly involve the binding and nuclear transloca-
tion of specific cytoplasmic receptors. These receptors can act as transcription factors and regulate gene expression. 
However, steroid-dependent transcriptional regulation in different types of neural cells is not yet fully understood. The 
aim of this study was to evaluate and compare transcriptional alterations induced by various steroid receptor agonists 
in primary cultures of astrocytes and neurons from mouse brain.
Results: We utilized whole-genome microarrays (Illumina Mouse WG-6) and quantitative PCR analyses to measure 
mRNA abundance levels. To stimulate gene expression we treated neuronal and astroglial cultures with dexametha-
sone (100 nM), aldosterone (200 nM), progesterone (200 nM), 5α-dihydrotestosterone (200 nM) and β-Estradiol 
(200 nM) for 4 h. Neurons were found to exhibit higher levels of expression of mineralocorticoid receptor, progester-
one receptor and estrogen receptor 2 than astrocytes. However, higher mRNA level of glucocorticoid receptor mRNA 
was observed in astrocytes. We identified 956 genes regulated by steroids. In astrocytes we found 381 genes altered 
by dexamethasone and 19 altered by aldosterone. Functional classification of the regulated genes indicated their 
putative involvement in multiple aspects of cell metabolism (up-regulated Slc2a1, Pdk4 and Slc45a3) and the inflam-
matory response (down-regulated Ccl3, Il1b and Tnf). Progesterone, dihydrotestosterone and estradiol did not change 
gene expression in astrocytes. We found no significant changes in gene expression in neurons.
Conclusions: The obtained results indicate that glial cells might be the primary targets of transcriptional action of 
steroids in the central nervous system. Substantial changes in gene expression driven by the glucocorticoid receptor 
imply an important role for the hypothalamic–pituitary–adrenal axis in the hormone-dependent regulation of brain 
physiology. This is an in vitro study. Hence, the model may not accurately reflect all the effects of steroids on gene 
expression in neurons in vivo.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The crucial components of the neuroendocrine system 
are steroid hormones. They affect the central nervous 
system by regulating allostasis and by coordinating the 
responses to external and internal stimuli [1]. The most 
prominent example of steroid impact on the brain is the 
release of glucocorticoids after stressful stimulus [2]. Ele-
vated levels of these adrenal steroids may subsequently 
affect sleep [3], cognition [4], memory [5] or mood [6]. 
Moreover, our previous research revealed that gluco-
corticoids mediate the effects on gene expression in the 
striatum induced by multiple psychoactive drugs, includ-
ing antidepressants (fluoxetine, mianserin), antipsychot-
ics (risperidone, clozapine) and drugs of abuse (heroin, 
ethanol) [7, 8]. This is probably caused by both direct 
and indirect actions of psychoactive drugs on the hypo-
thalamus and later on the pituitary and adrenal glands 
[8]. Furthermore, the association between dysregulation 
of the hypothalamic–pituitary–adrenal (HPA) axis and 
major depression is among the most consistent biologi-
cal findings in psychiatry [9]. The other steroids including 
Open Access
BMC Neuroscience
*Correspondence:  marpiech@if-pan.krakow.pl 
1 Department of Molecular Neuropharmacology, Institute 
of Pharmacology Polish Academy of Sciences, Smetna 12,  
31-343 Kraków, Poland
Full list of author information is available at the end of the article
Page 2 of 9Piechota et al. BMC Neurosci  (2017) 18:37 
mineralocorticoids, androgens, estrogens and progesto-
gens also influence the central nervous system [10, 11].
Steroids bind to nuclear steroid receptors, which then 
bind to their response elements on DNA, activating 
gene transcription and causing changes in gene expres-
sion. The alterations in transcript abundance mediated 
by these receptors are diverse and vary among cell types. 
It has been shown that the cell-type-specific profile of 
glucocorticoid receptor occupancy is predetermined by 
differences in the chromatin accessibility pattern [12]. 
Moreover, various cell populations differ in levels of 
steroid receptor genes expression. The most remarkable 
difference between various cell types in the central nerv-
ous system is high expression of progesterone receptor 
(Pgr) in neurons in contrast to glial and epithelial cells 
[13]. This cellular specificity contrasts with the lower 
specificity of steroid receptor ligands and DNA response 
elements. For example, corticosterone—an adrenal ster-
oid—binds to both mineralocorticoid and glucocorticoid 
receptors [14]. Furthermore, the differences in androgen 
and glucocorticoid receptor DNA binding properties are 
quantitative rather than qualitative [15].
The crucial aspect of steroids action on the central 
nervous system is how these hormones affect various 
cellular populations involved in control of behaviour. It 
is particularly interesting in the striatum, a brain region 
that is responsible for steroid-related neuropsychiatric 
phenotypes including mood control [16] and reward 
processing [17]. To date, there have been few studies 
comparing various neural cell-type-specific responses 
to steroids. Slezak et  al. [18] compared the responses 
of astrocytes and neurons to dexamethasone. Jenkins 
et al. [19] compared the responses of oligodendrocytes, 
astrocytes and microglia to the same steroid. The tran-
scriptional responses of these cell types to dexametha-
sone were diverse. Therefore, we aimed to infer the role 
of various steroids in the function of astrocytes and 
neurons, based on gene expression changes caused by 
these substances. Here, we present gene expression 
profiling of primary neuronal and astroglial cultures 
treated with various steroid receptor agonists: dexa-




The animals used in the study were from the C57BL/6 J 
inbred strain colony that is maintained at the animal 
facility of the Institute of Pharmacology of the Polish 
Academy of Sciences in Krakow, Poland. The mice were 
housed 6–10 per cage, under a 12-h dark/light cycle, with 
free access to food and water. The mice had not been 
subjected to any prior testing. The experimental proto-
cols used in the study were approved by the local Bioeth-
ics Commission at the Institute of Pharmacology, Polish 
Academy of Sciences (Krakow, Poland).
Primary cultures of striatal neurons and astrocytes
The ex  vivo experiments were conducted using mouse 
striatal neurons and astrocytes from primary cultures. 
Neuronal tissues were dissected from mouse embryos at 
17–18 days of gestation. The tissues were cut into small 
pieces and digested with trypsin (0.1% for 15  min at 
RT). The cells were suspended in Neurobasal® medium 
(Gibco) and plated onto polyornithine multiwell plates 
(TPP). After 2  days, the culture medium was replaced 
with Neurobasal medium supplemented with B27 
(50  μl/100  ml). This procedure typically yields cultures 
that contain >90% neurons (Fig.  1). Primary astrocytes 
were isolated from P5 to P7 mice. The brains were col-
lected, dissected and digested using the Neural Tissue 
Dissociation Kit (T) (Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany) according to the manufacturer’s 
protocol. Astrocytes from single-cell suspensions were 
isolated using the Anti-GLAST (ACSA-1) MicroBead 
Kit (Miltenyi Biotec), separated on MACS MS Columns 
using the MACS magnetic separator, seeded on 24-well 
plates and grown in high-glucose DMEM supplemented 
with 10% FBS and antibiotics for 7 days. All cell cultures 
were maintained at 37  °C in a humidified atmosphere 
containing 5% CO2 for 7 days prior to experiments. Both 
astrocytes and neurons were cultured in Neurobasal 
medium with no supplementation for the final 24 h.
Steroid ligands ex vivo treatments
Both neurons and astrocytes were exposed to dexa-
methasone (100  nM), corticosterone (10, 50 and 
200 nM) aldosterone (200 nM), progesterone (200 nM), 
5α-dihydrotestosterone (200  nM), or β-Estradiol 
(200 nM) for 4 h and 8 h (corticosterone only). The doses 
were selected based on previous studies [20–22]. To 
obtain stock solutions 1 mg of each compound was was 
dissolved in 100% ethanol and then diluted 50 times in 
neurobasal medium without supplements. As a result 
of dissolution we obtained stock solutions of dexa-
methasone (51 μM), corticosterone (57 μM), ß-estradiol 
(73 μM), progesterone (64 μM), aldosterone (55 μM) and 
testosterone (69 μM). The highest final solution of etha-
nol in culture medium was below 0.004% and this con-
centration was used as the vehicle negative control. The 
4  h time point was selected based on previous in  vitro 
studies using dexamethasone [18] and in  vivo studies 
using progesterone and glucocorticoid receptor antago-
nist RU486 [8].
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RNA isolation
RNA was isolated following the manufacturer’s protocol 
and was further purified using the RNeasy Mini Kit (Qia-
gen Inc.). Total RNA concentration was measured using 
a NanoDrop ND-1000 (NanoDrop Technologies Inc., 
Montchanin, DE, USA). RNA quality was determined 
using an Agilent 2100 Bioanalyzer (RIN  >  8)(Agilent, 
Palo Alto, CA, USA).
Quantitative PCR
Reverse transcription was performed using Omniscript 
Reverse Transcriptase (Qiagen Inc.). TaqMan® probes 
(Life Technologies) were used for the qPCR assays, 
which were run on the CFX96 Real-Time system (Bio-
Rad). Each template was generated from an individual 
sample, and the amplification efficiency for each assay 
was determined by running a standard dilution curve. 
Expression of the hypoxanthine–guanine phosphoribo-
syltransferase 1 (Hprt1) transcript, which showed stable 
levels following the treatment was quantified to control 
for variation in cDNA amounts. The abundance of RNA 
was calculated as 2−(threshold cycle). Data were analyzed 
using Student’s t test.
Gene expression profiling
First, 200 ng high-quality total RNA was used to gener-
ate cDNA and cRNA with the Illumina TotalPrep RNA 
Amplification Kit (Illumina Inc., San Diego, CA, USA). 
The procedure consisted of reverse transcription with 
an oligo(dT) primer bearing a T7 promoter using an 
Array-Script. The obtained cDNA became a template 
for in vitro transcription using T7 RNA polymerase and 
Fig. 1 Primary cell cultures of neurons and astrocytes. The purity was estimated by immunostaining for specific protein markers. (a) Neuronal 
cultures were immunostained on glass slides against MAP2 protein (red), GFAP astrocyte specific protein (green) and DAPI (blue). The staining 
confirmed at least 90% purity of neuronal cultures from the mouse striatum. (b) Primary astrocytes stained against GFAP (green), MAP2 (red) and 
DAPI (blue). (c) Primary astrocytes stained against GFAP (green), NEUN (red) and DAPI (blue). (d) The enrichment of astrocytes was determined by 
flow cytometry of immunostained GLAST-positive cells isolated from the brains of 5 days old C57BL/6 J mice. Approximately 80% of the cells were 
GLAST-positive astrocytes after the separation on MACS columns
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biotin UTP, which generated multiple copies of bioti-
nylated cRNA. The purity and concentration of the cRNA 
were checked using an ND-1000 Spectrometer. Quality 
cRNA was then hybridized using Illumina’s direct hybrid-
ization array kit (Illumina). Each cRNA sample (1.5  μg) 
was hybridized overnight to the MouseWG-6 BeadChip 
arrays (Illumina) in a multiple-step procedure accord-
ing to the manufacturer’s instructions; the chips were 
washed, dried and scanned on the BeadArray Reader 
(Illumina). Raw microarray data were generated using 
BeadStudio v3.0 (Illumina). Four biological replicates of 
the microarrays were prepared per experimental group. 
A total of 48 Illumina MouseWG-6 v2 microarrays (with 
probes for approximately 48,000 transcripts) were used 
in the experiment. To provide an appropriate balance in 
the whole dataset, groups were equally divided between 
the array hybridization batches.
Microarray data analysis
Microarray quality control was performed using BeadAr-
ray R package. The following parameters were checked: 
number of outliers, number of beads and percentage of 
probes detected. After background subtraction, the data 
were normalized using quantile normalization and then 
log2-transformed. The obtained signal was taken as the 
measure of mRNA abundance derived from the level of 
gene expression. Statistical analysis of the results was 
performed using two-way ANOVA (for the factors drug 
and cell type) followed by false discovery rate (FDR) 
correction for multiple testing. To obtain drug-versus-
control comparisons, a t-test was used followed by FDR 
correction. All statistical analyses were performed in R 
software.
Cluster analysis
Hierarchical clustering was performed using the measure 
of correlation and complete linkage method. The cluster 
separation was performed based on up- and downregu-
lation of transcripts. The functional annotation analysis 
tool DAVID was used to identify over-represented onto-
logic groups among the gene expression patterns and to 
group genes into functional classifications. For cell-type 
enrichment of mRNA, a recently published brain tran-
scriptome database was used  [13]. The identification of 
over-represented transcription factor binding sites was 
performed using the seqinspector database with default 
parameters [23].
Results
Differences in transcripts levels of steroid receptors 
between astroglial and neuronal primary cultures
We estimated levels of nuclear steroid receptors in neu-
ronal and astroglial primary cultures using quantitative 
PCR (Fig.  2; upper panel). There was no difference 
between neurons and astrocytes in the expression of 
androgen receptor (Ar) and estrogen receptor 2 (Esr2) 
(p > 0.05). Neurons showed higher expression of miner-
alocorticoid receptor (Nr3c2) (p = 0.0005), progesterone 
receptor (Pgr) (p = 3.6 × 10−7), and estrogen receptor 1 
(Esr1) (p =  1.1 ×  10−6). Astrocytes showed higher lev-
els of abundance of glucocorticoid receptor (Nr3c1) 
(p = 7.4 × 10−7). In addition, to compare mRNA levels 
between the receptors we used the available RNA-seq 
data from previous experiments by Piechota et  al. [24] 
(Fig.  2; middle panel) and by Zhang et  al. [13] (Fig.  2; 
lower panel). Consistent with the qPCR results, the pre-
viously published RNA-Seq studies by Piechota et al. [24] 
showed higher levels of expression of Nr3c2, Pgr and Esr1 
in neurons and higher levels of expression of Nr3c1 in 
astrocytes. RNA-seq data published by Zhang et al. [13] 
were similar to qPCR results with two differences—astro-
cytes exhibited higher levels of Nr3c2, and mRNA of Esr1 
was undetected.
Transcriptome alterations induced by steroid receptors 
agonists
We treated neuronal and astroglial primary cultures with 
dexamethasone (100 nM), aldosterone (200 nM), proges-
terone (200 nM) and estradiol (200 nM) for 4 h. For gene 
expression profiling, we used Illumina Mouse WG-6 v2 
microarrays. By performing two-way ANOVA (with the 
factor cell type and drug) we identified 956 genes regu-
lated by steroids (FDR < 1%). In astrocytes we found 381 
genes altered by dexamethasone (t test, FDR 1%), 19 by 
aldosterone, 0 by progesterone (9 at FDR 20% thresh-
old), and 0 by dihydrotestosterone and estradiol. In neu-
rons we identified 0 genes regulated by dexamethasone 
(19 at FDR 20%), and 0 by aldosterone, progesterone, 
dihydrotestosterone and estradiol. We performed gene 
ontology analysis of genes regulated by dexamethasone 
(n = 381), aldosterone (n = 19) and progesterone (n = 9 
at less restrictive threshold). The complete lists of regu-
lated genes are presented in the supplementary materials 
(Additional file 1).
We performed functional analyses of genes regulated by 
dexamethasone, aldosterone and progesterone. Using the 
DAVID tool we looked for overrepresented gene ontol-
ogy terms and molecular pathways. We found that genes 
upregulated by dexamethasone are functionally hetero-
geneous and include only a few overrepresented terms: 
positive regulation of cell proliferation (p = 1.0 × 10−5; 
FDR = 0.014; e.g. Bcl2l1, Cdkn1a, Trp63), negative regu-
lation of inflammatory response (p = 0.0015; FDR = 0.21; 
Ada, Zfp36), cell junction (p  =  0.012; FDR  =  0.36; 
Amica1, Gjb6). The genes downregulated by dexametha-
sone are functionally related to the immune response: 
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toll-like receptor signaling pathway (p  =  5.7  ×  10−8; 
FDR  =  4.1  ×  10−6; Ccl3, Il1b, Tnf), cytokine–cytokine 
receptor interaction (p = 5.2 × 10−5; FDR = 1.9 × 10−3; 
Ccl12, Cxcr10), or immune response (p  =  1.2  ×  10−4; 
FDR  =  0.098; Tlr2, Igh-6). We did not find any over-
represented terms for genes regulated by aldosterone or 
progesterone.
We evaluated transcriptional mechanisms control-
ling gene expression using the seqinspector tool [23] 
that utilize previously published ChIP-seq experi-
ments [12, 25]. Promoters of genes upregulated by 
dexamethasone in astrocytes were enriched in ChIP-seq 
signal for glucocorticoid receptor (SRA id: SRA027300, 
p  =  16  ×  10−10). Promoters of genes downregu-
lated by dexamethasone in astrocytes have binding 
sites for E2F1 (GEO id: GSM881059, p  =  5.2  ×  10−8), 
REL (GEO id: GSM881134, p  =  4.7  ×  10−6), RELA 
(GEO id: GSM881114, p  =  6.0  ×  10−6), JUNB (GEO 
id: GSM881079, p  =  6.3  ×  10−6), STAT2 (GEO 
id: GSM881162, p  =  5.3  ×  10−5), IRF4 (GEO id: 
GSM881150, p  =  5.9  ×  10−5), NFKB1 (GEO id: 
GSM881154, p  =  1.2  ×  10−4). Promoters of genes 
Fig. 2 Levels of steroid hormone receptors in astroglial and neuronal primary cultures. Bar graphs (upper left) summarizing the qPCR-based meas-
urement of gene expression of steroid nuclear receptors Nr3c1, Nr3c2, Pgr, Ar, Esr1, Esr2 (n = 4–6). Significant differences in the expression between 
astrocytes and neurons are indicated by asterisks (t test, ***p < 0.001). Bar graphs (bottom left) summarizing RNA-seq-based measurement of gene 
expression of steroid nuclear receptors [24]. Bar graphs summarizing RNA-seq-based measurement of gene expression of steroid nuclear receptors 
as reported by [13]. Technique and tissue from which the primary cultures were derived are indicated in the titles of the particular plots
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upregulated by aldosterone in astrocytes contain bind-
ing sites for glucocorticoid receptor (SRA id: SRA027300, 
p  =  1.1  ×  10−14). Genes regulated by progesterone in 
astrocytes have binding sites for BHLHE40 (GEO id: 
GSM912922, p = 2.3 × 10−9) and glucocorticoid receptor 
(SRA id: SRA027300, p = 8.7 × 10−9).
Gene expression changes induced by corticosterone
We compared transcriptional alterations induced by dexa-
methasone and aldosterone to endogenous non-specific 
glucocorticoid and mineralocorticoid receptors agonist, 
corticosterone. The effects of corticosterone on gene 
expression were measured in neurons and astrocytes in 
time and dose dependent manner by using quantitative 
PCR. From the list of genes detected by microarray pro-
filing we selected three previously known glucocorticoid-
receptor-dependent transcripts (Fkbp5, Zbtb16 and Sgk1) 
(Fig. 3). For statistical analysis we used three way ANOVA 
for cell type, dose and time factors. Interaction between 
factors was statistically significant (p  <  0.05) for all of 
the transcripts examined. Tukey HSD test was used as a 
post hoc test. All inspected transcripts were significantly 
upregulated in astrocytes (at doses of 50 nM and 200 nM) 
in both 4  h and 8  h time points. None of the inspected 
transcripts were significantly regulated in neuronal cells.
Glial enrichment of dexamethasone induced gene 
expression alterations in neurons
We observed that the genes induced in neurons (top 
20, t test FDR < 26%) were expressed at higher levels in 
astrocytes (p =  0.0017, t test between expression levels 
for controls in neurons and astrocytes). Using the top 
100 genes identified by two-way ANOVA in the whole 
experiment and compared fold induction of astroglia and 
neuron-specific genes in dexamethasone treated neu-
rons (Fig. 4). In neuronal primary cultures, we observed 
higher induction of dexamethasone-induced astroglia 
enriched genes than dexamethasone-induced neuron 
enriched genes (p = 0.032, t test between fold changes in 
gene expression) (Fig. 5).
Discussion
The most remarkable observation of this study was the 
weak, or absent response of neurons to hormonal stimu-
lus. As has previously been suggested, the main compo-
nent of transcriptional response to adrenal steroids is 
not neuronal but astroglial [8, 26, 27]. This hypothesis 
was based on astrocyte-specific gene enrichment (higher 
level of expression) among glucocorticoid inducible tran-
scripts [26]. In our previous studies, we have also shown 
that an inducible form of Sgk1 is present in astrocytes and 
not in neurons [18]. In that study, we found that, unlike 
astrocytes, neurons are not transcriptionally respon-
sive to dexamethasone treatment. We hypothesized that 
Fig. 3 Dexamethasone-induced regulation of astroglia specific 
genes in neuronal primary cultures. The bar graph summarizes the 
induction of gene expression in neurons after dexamethasone treat-
ment. Two groups of genes are presented: astrocyte-specific genes 
(log2 ratio of astroglial to neuronal expression higher than 2) and 
neuron-specific genes (log2 ratio of astroglial to neuronal expression 
lower than −2)
Fig. 4 Steroid receptor agonist induced transcriptome alterations. 
Microarray results are shown as a heat map and include the top 100 
genes with significant differences shown by two-way ANOVA for the 
drug factor. Colored rectangles represent transcript abundance in 
neurons and astrocytes in control samples (CTRL) and after treatment 
with dexamethasone (DEX), aldosterone (ALD), progesterone (PG), 
dihydrotestosterone (DHT) or estradiol (ES). The intensity of the color 
is proportional to the standardized values (blue low, red high). Cluster-
ing was performed using correlation distance and complete tree-
building method. Particularly interesting gene symbols are shown 
on the right. The data for neurons and astrocytes were adjusted for 
means in the control groups to better visualise the effects of steroid 
compounds. FPKM—fragments per kilobase of exon per million frag-
ments mapped
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in the previous experiments, the lack of transcriptional 
response of neurons to dexamethasone might have been 
caused by cell culture conditions and low concentration 
of dexamethasone (10  nM). Thus, in this study neurons 
and astrocytes were cultured in the same manner for the 
final 3  days. However, despite all those previous indi-
cations, we were startled by the low induction of gene 
expression in neurons. The most unexpected result was 
the lack of response of neurons to progesterone, despite 
the high expression of progesterone receptor [13] and the 
promotion of neuronal survival by this steroid [28, 29]. 
The presented in vitro study has several limitations. The 
model may not accurately reflect the effect of steroids on 
gene expression in neurons in the brain. It is possible that 
neurons isolated from embryonic tissue are subsensitive 
to steroids. Such a mechanism may insulate the brain 
from developmental interference from external steroids 
such as xenobiotic or maternally-generated steroids. 
Neonatal neurons cultured for 7 days are not fully devel-
oped and may have a lower number of functional syn-
apses compared to mature cells. Moreover, our study was 
designed to detect changes with twofold or higher, with 
a power of >50%. Thus, smaller changes in mRNA abun-
dance levels in neurons might have gone undetected.
Neither neurons nor astrocytes responded to estra-
diol or dihydrotestosterone, likely because of low levels 
of these receptors in our cultures. Although these ster-
oids have not acted transcriptionally in our case, they 
might act on membrane channels and receptors such 
as GABAA [30]. Although the astrocytes express far 
fewer progesterone receptors [13] than do neurons, they 
responded to progesterone transcriptionally. Neverthe-
less, this response was much weaker than those caused 
by dexamethasone or aldosterone. Astrocytic response 
to dexamethasone and aldosterone were qualitatively 
similar. This pattern of transcriptional activation was 
also detected in neuronal cells. However, the profile of 
changes indicates the very small number of contaminat-
ing astrocytes as a source of gene expression alterations. 
These results suggest that in our experiment response of 
neuronal cells to steroid hormones is repressed.
The mechanism of steroid nuclear receptor repres-
sion in neurons is intriguing. Our first hypothesis was 
focused on non-active isoforms of these receptors. We 
Fig. 5 Effects of corticosterone on gene expression of selected genes in astrocytes and neurons. Bar graphs summarizing the qPCR-based measure-
ments of changes in the expression of selected genes following the indicated corticosterone dose and time. Data are presented as the fold change 
over the control group (without corticosterone) ± standard deviation (n = 3–4). Significant differences from the post hoc analysis using a Tukey’s 
honest significant difference test (vs. appropriate control) by asterisks (***p < 0.001, **p < 0.01 and *p < 0.05)
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verified this speculation by reviewing the RNA-seq brain 
gene expression atlas [13] and FANTOM5 cage data [31]. 
In fact, the transcriptional isoform of Pgr expressed in 
neurons is shorter and has not been previously anno-
tated in the Ensembl database. However, neurons and 
astrocytes express the same transcriptional isoforms of 
Nr3c1 and Nr3c2, which disproves this conjecture. Our 
second hypothesis concerned the absence of nuclear 
receptor binding sites in neurons. The chromatin avail-
ability predetermines the binding sites of glucocorticoid 
receptor [12]. Nonetheless, such a complete blockade is 
rather unlikely. Our third hypothesis involves an imbal-
ance between coactivators and corepressors of steroid 
receptors in neurons which would inhibit their transcrip-
tional activity [32–34] and would allow only nongenomic 
mechanisms of action [35, 36] (see expanded discussion 
in Additional file 2).
The genes regulated in astrocytes in  vitro by dexa-
methasone overlap with other studies of transcriptional 
alterations induced by steroids in  vivo. Nine out of the 
top ten genes regulated by dexamethasone in mouse 
hypothalamus are also regulated in primary astro-
cytes (i.e. Gadd45 g, Sgk1, Pdk4, Nfkbia, Plekhf1, Errfi1, 
Arrdc2, Dusp1 and Bcl6) [37]. Similarly, multiple genes 
regulated by corticosterone in the rat hippocampus 
were identified in the presented study (e.g. Bcl6, Fkbp5, 
Gjb6, Errfi1, Pdk4) [38]. The genes upregulated by dexa-
methasone and aldosterone in astrocytes are function-
ally heterogeneous, which suggests diverse molecular 
mechanisms of action. One of these mechanisms may 
be related to the regulation of energy supply to neuronal 
cells. Genes involved in this process include a major glu-
cose transporter in the mammalian blood–brain barrier 
Slc2a1 [39], which was upregulated after dexamethasone 
or aldosterone treatment. Another gene Pdk4 maintains 
pyruvate dehydrogenase in the phosphorylated, inactive 
state and shunts pyruvate to form lactate in astrocytes 
[13]. Dexamethasone also upregulates the putative sugar 
transporter Slc45a3 [40]. Another set of regulated genes 
represents control of a negative feedback on the action 
of steroids. The genes involved in this process include 
Fkbp5 [41] and Hspa1b [42]. Astrocytes also show 
upregulation of the cell adhesion molecules Amica1 and 
Gjb6, which might influence the extracellular matrix and 
support neuronal plasticity. The genes downregulated 
by dexamethasone are homogeneous and are involved 
in inflammatory response. Dexamethasone can effec-
tively attenuate the inflammatory response to wounding, 
reducing neuronal and glial scarring in the vicinity of the 
wound [43].
Conclusions
Our study sheds new light on the mechanisms of action 
of steroid hormones in the central nervous system. The 
results show that glial cells constitute a primary target for 
the rapid transcriptional action of steroids. Identification 
of genes that mediate effects of adrenal steroids on astro-
cytes revealed novel molecular mechanisms involved in 
regulation of brain metabolism and plasticity. The unex-
pectedly low transcriptional response of neuronal cells to 
steroids provides rationale for further in vivo studies on 
this issue.
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